Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H7N2O5.Na |
Molecular Weight | 330.2269 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OC1=CC(=NC2=C1C3=NC4=CC=CC=C4OC3=CC2=O)C([O-])=O
InChI
InChIKey=HDQXPMXHXZNPKE-UHFFFAOYSA-M
InChI=1S/C16H8N2O5.Na/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12;/h1-6H,(H,18,19)(H,21,22);/q;+1/p-1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/21850160Curator's Comment: description was created based on several sources, including, http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160
Curator's Comment: description was created based on several sources, including, http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9
Pirenoxine is an anti-cataract agent which is used in many asian countries under the name Catalin. Although its efficacy is not proved scientifically, the drug may play an important role in cataract prevention. It is supposed that the anti-cataract effect of pirenoxine results from inhibition of sulfhydryl combination of quinoid substances with lens proteins and the inhibition leads to the maintenance of lens transparency.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0036438 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | CATALIN Approved UseEarly stage of senile cataract. |
Sample Use Guides
Dissolve the granules (0.75 mg) in 15 ml of the vehicle just before use and instill 1-2 drops of the
solution, 3-5 times a day
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160
Pirenoxine (1,000 uM) decreased UVC-induced turbidity formation compared to controls after 4 h of UVC exposure. The absolute gamma-crystallin turbidity induced by 4 h of UVC exposure was ameliorated in the presence of catalin equivalent to 1-100 uM of the drug in a concentration-dependent manner. Pirenoxine at 0.03, 0.1, and 0.3 uM significantly delayed 10 mM selenite- and calcium-induced turbidity formation compared to controls on days 0-4.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
23695982
Created by
admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
|
PRIMARY | |||
|
DTXSID1046637
Created by
admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
|
PRIMARY | |||
|
257-181-6
Created by
admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
|
PRIMARY | |||
|
SUB20995
Created by
admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
|
PRIMARY | |||
|
100000087311
Created by
admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
|
PRIMARY | |||
|
m8873
Created by
admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
|
PRIMARY | Merck Index | ||
|
51410-30-1
Created by
admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
|
PRIMARY | |||
|
95JU7URF64
Created by
admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD